Omada Health Partners with Optum Rx in Weight Engage Program
Omada Health has entered a strategic agreement with Optum Rx, one of the leading pharmacy benefit management firms, to participate in its innovative Weight Engage program. This collaboration is set to enhance Omada Health’s ability to expand its services, providing vital cardiometabolic care and support to a broader audience.
Addressing the Demand for GLP-1 Medications
The Weight Engage program was launched by Optum Rx in response to the increasing demand for GLP-1 medications. These drugs are sought after by numerous patients, yet they often encounter inconsistent coverage and several obstacles in accessing them. Optum highlighted the challenges of medication adherence, with some patients experiencing side effects or inadequate responses to the medication. Hence, a comprehensive, holistic model is essential for supporting patients on their healthcare journeys.
The Role of Omada Health
Omada Health plays a crucial role in this program. Besides Omada, Optum Rx is collaborating with Calibrate and Virta Health, underscoring the program’s focus on comprehensive care. Omada’s President, Wei-Li Shao, explained in an interview with Fierce Healthcare that the company’s platform aims to bridge gaps in patient care, facilitating long-term care pathways and promoting medication adherence.
Omada Health provides GLP-1 prescriptions under clinical supervision and connects patients to personalized support programs. This approach addresses significant issues like access and affordability, particularly for individuals grappling with obesity and cardiovascular diseases.
Benefits for Employers and Workforce
According to Shao, the partnership with Optum Rx and the broader Weight Engage program present a significant advantage for employers. Many companies are eager for solutions that align with the needs and expectations of their workforce but often lack adequate options in their health insurance plans or pharmacy benefit management services. This collaboration expands the spectrum of choices available to these employers.
Shao mentioned that although many companies wish to cover GLP-1 medications, they struggle to find the appropriate approach. The partnership not only enhances Omada’s growth trajectory but also extends the availability of their tools to more employers. There is notable demand for such offerings, with interest extending to Omada’s other products, including their cholesterol control program.
“It’s really about the ability to deliver value and innovation, engagement, and results to our members,” Shao emphasized, marking a forward step in the healthcare solutions landscape.
For more information, visit the source link: Here
“`
